New drug cocktails aim to tame transplant complications in blood cancer patients

NCT ID NCT06859424

Recruiting now Disease control Sponsor: Center for International Blood and Marrow Transplant Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether new drug combinations can better prevent graft-versus-host disease (GVHD) in people with blood cancers who receive a stem cell transplant from a mismatched unrelated donor. About 358 participants will get either the standard GVHD prevention or one of two experimental combinations. Researchers will compare how well each approach prevents GVHD and relapse while keeping patients alive and healthy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Post-transplant cyclophosphamide (PTCy) combined with ruxolitinib, tacrolimus, and MMF, or with abatacept and tacrolimus

What this could lead to

If successful, this could identify a safer, more effective drug combination to prevent graft-versus-host disease, improving outcomes for blood cancer patients receiving stem cell transplants.

What could go wrong

This is a Phase 2 trial, so results are preliminary. The new combinations may not be better than standard care and could have unexpected side effects like infection or organ damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia Leukemia, B-Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoma myelodysplastic syndrome myelodysplastic syndrome with excess blasts myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA (CATEGORY) ACUTE LYMPHOID LEUKEMIA (ALL) AML (ACUTE MYELOGENOUS LEUKEMIA) CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) CML (CHRONIC MYELOGENOUS LEUKEMIA) LYMPHOMA MDS (MYELODYSPLASTIC SYNDROME) MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM (MPN) PROLYMPHOCYCTIC LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02446, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering
RECRUITING

New York, New York, 10065, United States
Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States
Stanford
RECRUITING

Palo Alto, California, 94304, United States
University of Alabama Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Kansas Medical Center
RECRUITING

Westwood, Kansas, 66205, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States